Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HSV529 vaccine in HSV-2 seropositive adults
NCT02571166Phase 1Completed
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- Nov 2015
- Primary completion
- Dec 2018
- Modality
- Oncolytic Viruses, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of HSV-529 in Herpes Simplex Virus Type 2 Infection (HSV-2), sponsored by Fred Hutchinson Cancer Center. Primary endpoint: Safety of HSV529 vaccine at 1 year. Started Nov 2015; status: completed.
02
Drugs
HSV-529
03
Conditions
Herpes Simplex Virus Type 2 Infection (HSV-2)
Beyond the preview
Go deeper on NCT02571166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02571166.